Disposition of 1547 shares by Patel Anish of Enliven Therapeutics at 25.0111 subject to Rule 16b-3

ELVN Stock   25.41  1.06  4.35%   
About 65% of all Enliven Therapeutics' investors are looking to take a long position. The analysis of overall sentiment of trading Enliven Therapeutics stock suggests that some investors are interested at this time. Enliven Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Enliven Therapeutics. Many technical investors use Enliven Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Enliven Therapeutics Officer Chief Operating Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3

Read at macroaxis.com
Disposition of 1547 common stock at 25.0111 of Enliven Therapeutics by Patel Anish on 24th of November 2024. This event was filed by Enliven Therapeutics with SEC on 2024-07-16. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Enliven Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Enliven Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Enliven Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Enliven Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Enliven Therapeutics Fundamental Analysis

We analyze Enliven Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enliven Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enliven Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Number Of Shares Shorted

Number Of Shares Shorted Comparative Analysis

Enliven Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Enliven Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Enliven Therapeutics stock to make a market-neutral strategy. Peer analysis of Enliven Therapeutics could also be used in its relative valuation, which is a method of valuing Enliven Therapeutics by comparing valuation metrics with similar companies.

Peers

Enliven Therapeutics Related Equities

KRONKronos Bio   10.34   
0%
100.0%
IMRXImmuneering Corp   3.90   
0%
37.0%
CMPXCompass Therapeutics   3.31   
0%
32.0%
MLTXMoonLake Immunotherapeuti   2.65   
0%
25.0%
NVCTNuvectis Pharma   2.52   
0%
24.0%
CGEMCullinan Oncology   2.51   
0%
24.0%
INBXInhibrx   1.17   
0%
11.0%
PMVPPmv Pharmaceuticals   0.63   
0%
6.0%
GOSSGossamer Bio   0.24   
0%
2.0%
GPCRStructure Therapeutics   0.03   
0%
1.0%
ELYMEliem Therapeutics   1.30   
12.0%
0%
AVTEAerovate Therapeutics   1.49   
14.0%
0%
CELCCelcuity LLC   1.53   
14.0%
0%
REPLReplimune   2.29   
22.0%
0%
LYRALyra Therapeutics   5.00   
48.0%
0%
When determining whether Enliven Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enliven Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enliven Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enliven Therapeutics Stock:
Check out Enliven Therapeutics Hype Analysis, Enliven Therapeutics Correlation and Enliven Therapeutics Performance.
To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.89)
Return On Assets
(0.21)
Return On Equity
(0.31)
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.